Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells
In recent years, the medical community has witnessed a growing interest in the use of adoptive immunotherapy in patients with malignant lesions refractory to standard treatments. Systemic administration of interleukin 2, in combination with the adoptive transfer of a patient's own activated imm...
Gespeichert in:
| Veröffentlicht in: | Mayo Clinic proceedings 1989-04, Vol.64 (4), p.451-465 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 465 |
|---|---|
| container_issue | 4 |
| container_start_page | 451 |
| container_title | Mayo Clinic proceedings |
| container_volume | 64 |
| creator | HAELST-PISANI, CAROL M. van PISANI, RICHARD J. KOVACH, JOHN S. |
| description | In recent years, the medical community has witnessed a growing interest in the use of adoptive immunotherapy in patients with malignant lesions refractory to standard treatments. Systemic administration of interleukin 2, in combination with the adoptive transfer of a patient's own activated immune cells, has resulted in objective regression of several types of advanced cancers. Pronounced regression of tumor has also been observed with use of systemic interleukin 2 alone. This ability to augment the immune defense system of the host against cancer has stimulated intense clinical and laboratory investigations. |
| doi_str_mv | 10.1016/S0025-6196(12)65736-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78976563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002561961265736X</els_id><sourcerecordid>78976563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-92d66357d568271806c6cb85f6cb0c4e8d7b50fe188ad3ce6b6f90cbc4458ff83</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EKkvhJ1TyCcEhYDvxxOGCqojCqitxaBG9WY490brkY7GdSvvv6-2ueu1lRjPzztdDyAVnXzjj8PWGMSEL4A184uIzyLqE4u4VWfGmEoWUFbwmq2fJW_IuxnvGWN001Rk5EyArycSK3LdmshjoehyXaU5bDGa3_0bbJQScEr1JJi2Rzj29DWjSeMj99WlL11PCMODyz09UUDM5utmPu-2cYywubfIPJqGj134Y8vQWhyG-J296M0T8cPLn5M_Vj9v2V7H5_XPdXm4KWwJLRSMcQClrJ0GJmisGFmynZJ8tsxUqV3eS9ciVMq60CB30DbOdrSqp-l6V5-Tjce4uzP8XjEmPPtp8gZlwXqKuVVODhDIL5VFowxxjwF7vgh9N2GvO9IGxfmKsDwA1F_qJsb7LfRenBUs3onvuOkHN9e_HOuYvHzwGHa3HjNn5gDZpN_sXNjwCI16NGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78976563</pqid></control><display><type>article</type><title>Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>HAELST-PISANI, CAROL M. van ; PISANI, RICHARD J. ; KOVACH, JOHN S.</creator><creatorcontrib>HAELST-PISANI, CAROL M. van ; PISANI, RICHARD J. ; KOVACH, JOHN S.</creatorcontrib><description>In recent years, the medical community has witnessed a growing interest in the use of adoptive immunotherapy in patients with malignant lesions refractory to standard treatments. Systemic administration of interleukin 2, in combination with the adoptive transfer of a patient's own activated immune cells, has resulted in objective regression of several types of advanced cancers. Pronounced regression of tumor has also been observed with use of systemic interleukin 2 alone. This ability to augment the immune defense system of the host against cancer has stimulated intense clinical and laboratory investigations.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/S0025-6196(12)65736-X</identifier><identifier>PMID: 2654502</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animals ; Humans ; Immunotherapy ; Interleukin-2 - therapeutic use ; Killer Cells, Natural - immunology ; Lymphokines ; Neoplasms - therapy</subject><ispartof>Mayo Clinic proceedings, 1989-04, Vol.64 (4), p.451-465</ispartof><rights>1989 Mayo Foundation for Medical Education and Research</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-92d66357d568271806c6cb85f6cb0c4e8d7b50fe188ad3ce6b6f90cbc4458ff83</citedby><cites>FETCH-LOGICAL-c360t-92d66357d568271806c6cb85f6cb0c4e8d7b50fe188ad3ce6b6f90cbc4458ff83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2654502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HAELST-PISANI, CAROL M. van</creatorcontrib><creatorcontrib>PISANI, RICHARD J.</creatorcontrib><creatorcontrib>KOVACH, JOHN S.</creatorcontrib><title>Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>In recent years, the medical community has witnessed a growing interest in the use of adoptive immunotherapy in patients with malignant lesions refractory to standard treatments. Systemic administration of interleukin 2, in combination with the adoptive transfer of a patient's own activated immune cells, has resulted in objective regression of several types of advanced cancers. Pronounced regression of tumor has also been observed with use of systemic interleukin 2 alone. This ability to augment the immune defense system of the host against cancer has stimulated intense clinical and laboratory investigations.</description><subject>Animals</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphokines</subject><subject>Neoplasms - therapy</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EKkvhJ1TyCcEhYDvxxOGCqojCqitxaBG9WY490brkY7GdSvvv6-2ueu1lRjPzztdDyAVnXzjj8PWGMSEL4A184uIzyLqE4u4VWfGmEoWUFbwmq2fJW_IuxnvGWN001Rk5EyArycSK3LdmshjoehyXaU5bDGa3_0bbJQScEr1JJi2Rzj29DWjSeMj99WlL11PCMODyz09UUDM5utmPu-2cYywubfIPJqGj134Y8vQWhyG-J296M0T8cPLn5M_Vj9v2V7H5_XPdXm4KWwJLRSMcQClrJ0GJmisGFmynZJ8tsxUqV3eS9ciVMq60CB30DbOdrSqp-l6V5-Tjce4uzP8XjEmPPtp8gZlwXqKuVVODhDIL5VFowxxjwF7vgh9N2GvO9IGxfmKsDwA1F_qJsb7LfRenBUs3onvuOkHN9e_HOuYvHzwGHa3HjNn5gDZpN_sXNjwCI16NGg</recordid><startdate>19890401</startdate><enddate>19890401</enddate><creator>HAELST-PISANI, CAROL M. van</creator><creator>PISANI, RICHARD J.</creator><creator>KOVACH, JOHN S.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890401</creationdate><title>Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells</title><author>HAELST-PISANI, CAROL M. van ; PISANI, RICHARD J. ; KOVACH, JOHN S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-92d66357d568271806c6cb85f6cb0c4e8d7b50fe188ad3ce6b6f90cbc4458ff83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphokines</topic><topic>Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAELST-PISANI, CAROL M. van</creatorcontrib><creatorcontrib>PISANI, RICHARD J.</creatorcontrib><creatorcontrib>KOVACH, JOHN S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAELST-PISANI, CAROL M. van</au><au>PISANI, RICHARD J.</au><au>KOVACH, JOHN S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>1989-04-01</date><risdate>1989</risdate><volume>64</volume><issue>4</issue><spage>451</spage><epage>465</epage><pages>451-465</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><abstract>In recent years, the medical community has witnessed a growing interest in the use of adoptive immunotherapy in patients with malignant lesions refractory to standard treatments. Systemic administration of interleukin 2, in combination with the adoptive transfer of a patient's own activated immune cells, has resulted in objective regression of several types of advanced cancers. Pronounced regression of tumor has also been observed with use of systemic interleukin 2 alone. This ability to augment the immune defense system of the host against cancer has stimulated intense clinical and laboratory investigations.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>2654502</pmid><doi>10.1016/S0025-6196(12)65736-X</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-6196 |
| ispartof | Mayo Clinic proceedings, 1989-04, Vol.64 (4), p.451-465 |
| issn | 0025-6196 1942-5546 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78976563 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Humans Immunotherapy Interleukin-2 - therapeutic use Killer Cells, Natural - immunology Lymphokines Neoplasms - therapy |
| title | Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T05%3A08%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20Immunotherapy:%20Current%20Status%20of%20Treatment%20With%20Interleukin%202%20and%20Lymphokine-Activated%20Killer%20Cells&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=HAELST-PISANI,%20CAROL%20M.%20van&rft.date=1989-04-01&rft.volume=64&rft.issue=4&rft.spage=451&rft.epage=465&rft.pages=451-465&rft.issn=0025-6196&rft.eissn=1942-5546&rft_id=info:doi/10.1016/S0025-6196(12)65736-X&rft_dat=%3Cproquest_cross%3E78976563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78976563&rft_id=info:pmid/2654502&rft_els_id=S002561961265736X&rfr_iscdi=true |